Clinical Trial Update: PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial updating PD-L1 inhibition as checkpoint immunotherapy for neuroendocrine phenotype prostate cancer completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• PD-L1 inhibitor (Programmed death-ligand 1 inhibitor)

Snippet

Sponsor: Andrew J. Armstrong, MD | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-03-05